Omicia develops the Opal Clinical platform, a cloud-enabled, HIPAA-compliant software suite for next-generation sequencing (NGS) interpretation, reporting, and automated diagnostic workflows. The platform leverages a deep variant data warehouse and white-label deployment to deliver high-throughput results and replace manual, costly in-house pipelines. Omicia’s products are used at more than 500 academic and clinical institutions worldwide. The company plans to extend variations of Opal into new geographies and verticals, including life science research, clinical trial support, population health management, and consumer applications. Omicia has offices in Oakland, California and the UK and is expanding its team and commercial operations to support growth. Financially, Omicia recently completed a $23 million Series B financing to accelerate product development and expand sales, marketing, support, and operations. Omicia develops scalable, fully integrated informatics systems—branded Opal—to interpret human genome sequences for research and clinical applications. Opal provides advanced tools that allow clinicians, researchers, and bioinformaticians to analyze genomes independently or collaboratively without specialized bioinformatics capabilities. The company positions Opal as a healthcare IT platform for fast, accurate and flexible genome analysis, aimed at deriving clinically relevant insights from genomic data. Omicia is based in the San Francisco Bay Area (Oakland) and focuses on commercializing its big-data genomics offerings. The company closed a $6.8 million Series A to expand marketing reach and further optimize its platform. Recent corporate moves include adding Tad Buchanan and William Gerber to the board alongside CEO Mike Aicher, chairman John Stuelpnagel DVM, and founder/president Martin Reese PhD. Omicia’s stated mission is to help scientists and clinicians understand the most relevant information from personal genome sequences and their potential medical consequences.

Total raised

$30M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2016